395 related articles for article (PubMed ID: 1280751)
1. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
Verhoef GE; De Schouwer P; Ceuppens JL; Van Damme J; Goossens W; Boogaerts MA
Leukemia; 1992 Dec; 6(12):1268-72. PubMed ID: 1280751
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum TNF-alpha concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes.
Alexandrakis M; Coulocheri S; Xylouri I; Ganotakis E; Eliakis P; Karkavitsas N; Eliopoulos GD
Haematologia (Budap); 1998; 29(1):13-24. PubMed ID: 9704253
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
4. Autologous stem cell transplantation: sequential production of hematopoietic cytokines underlying granulocyte recovery.
Baiocchi G; Scambia G; Benedetti P; Menichella G; Testa U; Pierelli L; Martucci R; Foddai ML; Bizzi B; Mancuso S
Cancer Res; 1993 Mar; 53(6):1297-303. PubMed ID: 7680283
[TBL] [Abstract][Full Text] [Related]
5. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
6. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3.
Maurer AB; Ganser A; Buhl R; Seipelt G; Ottmann OG; Mentzel U; Geissler RG; Hoelzer D
Leukemia; 1993 Nov; 7(11):1728-33. PubMed ID: 8231242
[TBL] [Abstract][Full Text] [Related]
7. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.
Musto P; Matera R; Minervini MM; Checchia-de Ambrosio C; Bodenizza C; Falcone A; Carotenuto M
Haematologica; 1994; 79(3):265-8. PubMed ID: 7926977
[TBL] [Abstract][Full Text] [Related]
8. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-specific reduction in the expression of granulocyte--macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes.
Shikama Y; Shichishima T; Ohto H; Jubinsky PT; Maruyama Y
Br J Haematol; 2000 Dec; 111(3):863-72. PubMed ID: 11122148
[TBL] [Abstract][Full Text] [Related]
10. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.
Asano H; Hotta T; Ichihara M; Murate T; Kobayashi M; Saito H
Leukemia; 1994 May; 8(5):833-8. PubMed ID: 7514249
[TBL] [Abstract][Full Text] [Related]
11. [Pattern of blood levels of erythropoietin and proinflammatory cytokines in patients with anemia of chronic disorders secondary to infection].
Poveda Gómez F; Camacho Siles J; Quevedo Morales E; Fernández Zamorano A; Codoceo Alquinta R; Arnalich Fernández F; Sempere Alcocer M
An Med Interna; 2001 Jun; 18(6):298-304. PubMed ID: 11503575
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte and granulocyte-macrophage colony-stimulating factors, their receptors and interleukin-3 levels in newborns.
Coşkun M; Kardelen F; Oygür N; Undar L; Savaş A; Yeğin O
Turk J Pediatr; 1997; 39(3):295-301. PubMed ID: 9339107
[TBL] [Abstract][Full Text] [Related]
13. [Influence of tumor necrosis factor-alpha and interferon-gamma on erythropoietin production and erythropoiesis in cancer patients with anemia].
Wang W; Zhang MH; Yu Y; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):681-4. PubMed ID: 18399174
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in treated patients with chronic myelogenous leukemia in chronic phase.
Balleari E; Bason C; Visani G; Gobbi M; Ottaviani E; Ghio R
Haematologica; 1994; 79(1):7-12. PubMed ID: 15378942
[TBL] [Abstract][Full Text] [Related]
15. Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome.
Dalamaga M; Karmaniolas K; Chamberland J; Nikolaidou A; Lekka A; Dionyssiou-Asteriou A; Mantzoros CS
Metabolism; 2013 Dec; 62(12):1830-9. PubMed ID: 24140093
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome.
Stasi R; Brunetti M; Bussa S; Conforti M; Martin LS; La Presa M; Bianchi M; Parma A; Pagano A
Clin Lab Haematol; 1997 Sep; 19(3):197-201. PubMed ID: 9352145
[TBL] [Abstract][Full Text] [Related]
17. Endogenous serum levels and surface receptor expression of GM-CSF and IL-3 in patients with myelodysplastic syndromes.
Zwierzina H; Schöllenberger S; Herold M; Schmalzl F; Besemer J
Leuk Res; 1992 Dec; 16(12):1181-6. PubMed ID: 1465026
[TBL] [Abstract][Full Text] [Related]
18. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
Thompson JA; Gilliland DG; Prchal JT; Bennett JM; Larholt K; Nelson RA; Rose EH; Dugan MH
Blood; 2000 Feb; 95(4):1175-9. PubMed ID: 10666187
[TBL] [Abstract][Full Text] [Related]
19. Increased levels of circulating cytokines in patients with untreated Hodgkin's disease.
Gause A; Keymis S; Scholz R; Schobert I; Jung W; Diehl V; Pohl C; Pfreundschuh M
Lymphokine Cytokine Res; 1992 Apr; 11(2):109-13. PubMed ID: 1581417
[TBL] [Abstract][Full Text] [Related]
20. Levels of soluble forms of ICAM and VCAM in patients with myelodysplastic syndromes and their prognostic significance.
Passam FH; Tsirakis G; Boula A; Fragou A; Consolas I; Alegakis A; Kyriakou DS; Alexandrakis MG
Clin Lab Haematol; 2004 Dec; 26(6):391-5. PubMed ID: 15595996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
